George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT; Department of Orthopaedics, University of Utah, Salt Lake City, UT.
George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT; Department of Orthopaedics, University of Utah, Salt Lake City, UT.
Arch Phys Med Rehabil. 2022 Nov;103(11):2092-2104. doi: 10.1016/j.apmr.2022.06.008. Epub 2022 Jul 29.
Evaluate the safety and efficacy of a novel press-fit bone-anchored prosthesis in an FDA approved study.
Single-center, prospective 1-year follow-up cohort study of a percutaneous bone anchored prosthesis.
Veterans Health Administration Hospital.
Ten male Veterans with unilateral transfemoral amputation that occurred at least 6 months prior to enrollment and was not the result of dysvascular disease (N=10).
All participants received the novel press-fit Percutaneous Osseointegrated Prosthesis (POP) and a minimum of 10 days supervised rehabilitation therapy.
Adverse events and radiographs were collected to assess device safety. Temporal assessments of bone density, stomal skin, prosthetic don/doff, functional ambulation, and patient-reported outcome compared our POP to a socket suspension system.
Ten male participants mean age 48.8±12.1 years (range, 32-68 y) with mean time since amputation of 9.4± years (range 1-18 y) completed a two-staged implantation protocol and progressed to ambulation with an assistive device by post-operative day 14. Eight of 10 completed all study procedures. One implant loosened at 5 weeks, requiring removal. A second was removed after periprosthetic fracture from a non-device-related fall at 28 weeks. One patient required oral antibiotics for superficial infection. There were significant (P<.05) increases in bone density in the lumbar spine and adjacent to the distal porous coating with no radiographic evidence of bone resorption. Compared to the socket system, the use of POP significantly (P<.05) reduced prosthetic don and doff times and patient-reported prosthetic problem scores. Significant improvements (P<.05) in mean mobility, global health, and walking test scores were also observed.
Improvements in bone density, function, and patient reported outcomes were observed with the POP device when compared to a socket suspension system. This Early Feasibility Study established initial safety and effectiveness of the POP device, supporting expanded investigation as an alternative to socket prostheses.
在 FDA 批准的研究中评估新型压配式骨锚定假体的安全性和有效性。
经皮骨锚定假体的单中心、前瞻性 1 年随访队列研究。
退伍军人健康管理局医院。
10 名男性退伍军人,单侧股骨截肢,发生于入组前至少 6 个月,且非血管疾病所致(N=10)。
所有参与者均接受新型压配式经皮骨整合假体(POP)和至少 10 天的监督康复治疗。
收集不良事件和 X 线片以评估器械安全性。对骨密度、造口皮肤、假体装卸、功能性步行和患者报告的结果进行时间评估,将我们的 POP 与插座悬挂系统进行比较。
10 名男性参与者的平均年龄为 48.8±12.1 岁(范围 32-68 岁),截肢后平均时间为 9.4±年(范围 1-18 岁),完成两阶段植入方案,并在术后第 14 天通过辅助设备进行步行。10 名参与者中有 8 名完成了所有研究程序。1 例在 5 周时松动,需要取出。另 1 例在 28 周时因与器械无关的跌倒导致假体周围骨折而取出。1 例患者因浅表感染需要口服抗生素。腰椎和远端多孔涂层附近的骨密度有显著增加(P<.05),无骨质吸收的放射学证据。与插座系统相比,使用 POP 可显著减少假体装卸时间和患者报告的假体问题评分(P<.05)。同时,也观察到平均活动能力、总体健康和步行测试评分的显著改善(P<.05)。
与插座悬架系统相比,使用 POP 装置可观察到骨密度、功能和患者报告结果的改善。这项早期可行性研究确立了 POP 装置的初步安全性和有效性,支持将其作为插座假体的替代方案进行更广泛的研究。